These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 31550029)

  • 1. Cannabinoid Agonist Reduces Cannabis Use.
    Slomski A
    JAMA; 2019 Sep; 322(12):1134. PubMed ID: 31550029
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use.
    Dean B; Sundram S; Bradbury R; Scarr E; Copolov D
    Neuroscience; 2001; 103(1):9-15. PubMed ID: 11311783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabis and cannabinoids: pharmacology and rationale for clinical use.
    Pertwee RG
    Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol.
    Romero J; García L; Fernández-Ruiz JJ; Cebeira M; Ramos JA
    Pharmacol Biochem Behav; 1995 Aug; 51(4):731-7. PubMed ID: 7675852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia.
    Müller-Vahl KR; Emrich HM
    Expert Rev Neurother; 2008 Jul; 8(7):1037-48. PubMed ID: 18590475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization.
    Braun M; Khan ZT; Khan MB; Kumar M; Ward A; Achyut BR; Arbab AS; Hess DC; Hoda MN; Baban B; Dhandapani KM; Vaibhav K
    Brain Behav Immun; 2018 Feb; 68():224-237. PubMed ID: 29079445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Progress in cannabis research from a pharmaceutical chemist's point of view].
    Müller CE
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2019 Jul; 62(7):818-824. PubMed ID: 31161229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacologic and clinical effects of medical cannabis.
    Borgelt LM; Franson KL; Nussbaum AM; Wang GS
    Pharmacotherapy; 2013 Feb; 33(2):195-209. PubMed ID: 23386598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabis: discrimination of "internal bliss"?
    Wiley JL
    Pharmacol Biochem Behav; 1999 Oct; 64(2):257-60. PubMed ID: 10515300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cannabis in digestive disorders.
    Goyal H; Singla U; Gupta U; May E
    Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):135-143. PubMed ID: 27792038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interrelationships of glandular trichomes and cannabinoid content. I: Developing pistillate bracts of Cannabis sativa L. (Cannabaceae).
    Turner JC; Hemphill JK; Mahlberg PG
    Bull Narc; 1981; 33(2):59-69. PubMed ID: 6914206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid Markers in Biological Fluids and Tissues: Revealing Intake.
    Huestis MA; Smith ML
    Trends Mol Med; 2018 Feb; 24(2):156-172. PubMed ID: 29398403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development.
    Pertwee RG
    Expert Opin Investig Drugs; 2000 Jul; 9(7):1553-71. PubMed ID: 11060760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
    van Amsterdam J; Brunt T; van den Brink W
    J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First systematic evaluation of the potency of Cannabis sativa plants grown in Albania.
    Bruci Z; Papoutsis I; Athanaselis S; Nikolaou P; Pazari E; Spiliopoulou C; Vyshka G
    Forensic Sci Int; 2012 Oct; 222(1-3):40-6. PubMed ID: 22608266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
    Rice J; Cameron M
    Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety issues concerning the medical use of cannabis and cannabinoids.
    Ware MA; Tawfik VL
    Pain Res Manag; 2005; 10 Suppl A():31A-7A. PubMed ID: 16237480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabis-associated psychosis: current status of research.
    Leweke FM; Gerth CW; Klosterkötter J
    CNS Drugs; 2004; 18(13):895-910. PubMed ID: 15521792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology.
    Potter DJ; Clark P; Brown MB
    J Forensic Sci; 2008 Jan; 53(1):90-4. PubMed ID: 18279244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.
    McRae-Clark AL; Baker NL; Gray KM; Killeen TK; Wagner AM; Brady KT; DeVane CL; Norton J
    Drug Alcohol Depend; 2015 Nov; 156():29-37. PubMed ID: 26386827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.